Weksler ME. Hormone replacement for men. Br Med J 1996;312:859-60
[editorial].
Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone.
Lancet 1994;343:1479-81.
Stomati M, Rubino S, Spinetti A, et al. Endocrine, neuroendocrine and
behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal
women. Gynecol Endocrinol 1999;13:15-25.
Labrie F, Belanger A, Simard J, et al. DHEA and peripheral androgen and
estrogen formation: Intracrinology. Ann NY Acad Sci 1995;774:16-28.
Reiter WJ, Pycha A, Schatzl G, et al. Dehydroepiandrosterone in the treatment
of erectile dysfunction: a prospective, double-blind randomized, placebo-controlled study.
Urology 1999;53:590-5.
Diamond P, Cusan L, Gomez J-L, et al. Metabolic effects of 12-month
percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J
Endocrinol 1996;150:S43-50.
Nestler JE, Barlasini CO, Clore JN, et al. Dehydroepiandrosterone reduces
serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in
normal men. J Clin Endocrinol Metab 1988;66:57-61.
Welle S, Jozefowicz R, Statt M. Failure of DHEA to influence energy and
protein metabolism in humans. J Clin Endocrinol Metab 1990;71:1259.
Usiskin KS, Butterworth S, Clore JN, et al. Lack of effect of
dehydroepiandrosterone in obese men. Int J Obes 1990;14:457-63.
Vogiatzi MG, Boeck MA, Vlachopapadopoulou E, et al. Dehydroepiandrosterone in
morbidly obese adolescents: effects on weight, body composition, lipids, and insulin
resistance. Metabolism 1996;45:1101-15.
Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women.
Ann NY Acad Sci 1995;774:128-42.
Diamond P, Cusan L, Gomez J-L, et al. Metabolic effects of 12-month
percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J
Endocrinol 1996;150:S43-50.
Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women.
Ann NY Acad Sci 1995;774:128-42.
Mortola J, Yen SSC. The effects of dehydroepiandrosterone on
endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab
1990;71:695-704.
Khorram O, Vu L, Yen SS. Activation of immune function by
dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A Biol Sci Med Sci
1997;52:M1-7.
Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in
physiologic doses modulates immune function in postmenopausal women. Am J Obstet
Gynecol 1993;169:1536-9.
Jessee RL, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human
platelet aggregation in vitro and in vivo. Ann NY Acad Sci 1995;29:281-90.
Schaefer C, Friedman G, Ettinger B, et al. Dehydroepiandrosterone sulfate
(DHEAS), angina, and fatal ischemic heart disease. Am J Epidemiol
1996;143(11suppl):S69 [abstr #274].
Barrett-Connor E, Goodman-Gruen D. The epidemiology of DHEAS and
cardiovascular disease. Ann NY Acad Sci 1995;774:259-70.
Johannes CB, Stellato RK, Feldman HA, et al. Relation of
dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk
factors in women: longitudinal results from the Massachusetts Women’s Health Study.
J Clin Epidemiol 1999;52:95-103.
Mortola J, Yen SSC. The effects of dehydroepiandrosterone on
endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab
1990;71:695-704.
Yen SSC, Morales AJ, Khorram O. Replacement of DHEA in aging men and women.
Ann NY Acad Sci 1995;774:128-42.
Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, et al. Dehydroepiandrosterone
replacement in aging humans. J Clin Endocrinol Metab 1999;84:1527-33.
Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA
sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl
Acad Sci U S A 2000;97:4279-84.
Lahita RG, Bradlow HL, Ginzler E, et al. Low plasma androgens in women with
systemic lupus erythematosus. Arthritis Rheum 1987;30:241-8.
van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in
systemic lupus erythematosus. Arthritis Rheum 1995;38:1826-31.
van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of
systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol 1998;25:285-9.
Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of DHEA
in men and women of advancing age. J Clin Endorcrionol Metab 1994;78:1360.
Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major
depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646-9.
Bloch M, Schmidt PJ, Danaceau MA, et al. Dehydroepiandrosterone treatment of
midlife dysthymia. Biol Psychiatry 1999;45:1533-41.
Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological
dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly
women and men. J Clin Endocrinol Metab 1997;82:2263-7.
Gaby AR. Research review. Nutr Healing, 1997;Jun: 8.
Araghiniknam J, Chung S, Nelson-White T, et al. Antioxidant activity of
dioscorea and dehydroepiandrosterone (DHEA) in older humans. Life Sci
1996;59:147–57.
Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone.
Lancet 1994;343:1479–81.
Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement
in women with adrenal insufficiency. N Engl J Med 1999;341:1013–20.
Gebre-Medhin G, Husebye ES, Mallmin H, et al. Oral dehydroepiandrosterone
(DHEA) replacement therapy in women with Addison’s disease. Clin Endocrinol
(Oxf) 2000;52:775–80.
Barrett-Connor E, von Mühlen D, Laughlin GA, Kripke A. Endogenous levels
of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed
mood in older women: The Rancho Bernardo Study. J Am Geriatr Soc
1999;47:685–91.
Heinz A, Weingartner H, George D, et al. Severity of depression in abstinent
alcoholics is associated with monoamine metabolites and dehydroepiandrosterone-sulfate
concentrations. Psychiatry Res 1999;89:97–106.
Heuser I, Deuschle M, Luppa P, et al. Increased diurnal plasma concentrations
of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab
1998;83:3130–3.
Azuma T, Nagai Y, Saito T, et al. The effect of dehydroepiandrosterone sulfate
administration to patients with multi-infarct dementia. J Neurol Sci
1999;162:69–73.
Ferrando SJ, Rabkin JG, Poretsky L. Dehydroepiandrosterone sulfate (DHEAS) and
testosterone: Relation to HIV illness stage and progression over one year. J Acquir Immune
Defic Syndr 1999;22:146–54.
Louviselli A, Pisanu P, Cossu E, et al. Low levels of dehydroepiandrosterone
sulfate in adult males with insulin-dependent diabetes mellitus. Minerva Endocrinol
1994;19:113–9.
Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of
dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in
proportion to the severity. J Clin Endocrinol Metab 2000;85:1834–40.
Kümpfel T, Then Bergh F, Friess E, et al. Dehydroepiandrosterone response
to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing
hormone test in patients with multiple sclerosis. Neuroendocrinology
1999;70:431–8.
Weinstein RE, Lobocki CA, Gravett S, et al. Decreased adrenal sex steroid in
the absence of glucocorticoid suppression in postmenopausal asthmatic women. J Allergy
Clin Immunol 1996;97:1–8.
Dunn PJ; Mahood CB; Speed JF; Jury DR. Dehydroepiandrosterone sulphate
concentrations in asthmatic patients: pilot study. N Z Med J
1984;97:805–8.
Kuratsune H, Yamaguti K, Sawada M, et al. Dehydroepiandrosterone sulfate
deficiency in chronic fatigue syndrome. Int J Mol Med 1998;1:143–6.
De Becker P, De Meirleir K, Joos E, et al. Dehydroepiandorsterone (DHEA)
response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res
1999;31:18–21.
Khalkhali-Ellis Z, Moore TL, Hendrix MJ. Clin Exp Rheumatol
1998;16:753–6.
Hall GM, Perry LA, Spector TD. Depressed levels of dehydroepiandrosterone
sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone
density. Ann Rheum Dis 1993;52:211–4.
Mateo L, Nolla JM, Bonnin MR, et al. Sex hormone status and bone mineral
density in men with rheumatoid arthritis. J Rheumatol 1995;22:1455–60.
Gaby AR. Dehydroepiandrosterone: biological effects and clinical significance.
Altern Med Rev 1996;1:60–9 [review].
Heikkila R, Aho K, Heliovaara M, et al. Serum androgen-anabolic hormones and
the risk of rheumatoid arthritis. Ann Rheum Dis 1998;57:281–5.
Mileva Zh, Maleeva A, Khristov G. Androstenedione, DHEA sulfate, cortisol,
aldosterone and testosterone in bronchial asthma patients. Vutr Boles.
1990;29:84–7 [in Bulgarian].
Reiter WJ, Pycha A, Schatzl G, et al. Serum dehydroepiandrosterone sulfate
concentrations in men with erectile dysfunction. Urology 2000;55:755–8.
Hillen T, Lun A, Reischies FM, et al. DHEA-S plasma levels and incidence of
Alzheimer’s disease. Biol Psychiatry 2000;47:161–3.
Nasman B, Olsson T, Backstrom T, et al. Serum dehydroepiandrosterone sulfate
in Alzheimer’s disease and in multi-infarct dementia. Biol Psychiatry
1991;30:684–90.
Sunderland T, Merril CR, Harrington MG, et al. Reduced plasma
dehydroepiandrosterone concentrations in Alzheimer’s disease. Lancet
1989;2:570.
Yanase T, Fukahori M, Taniguchi S, et al. Serum dehydroepiandrosterone (DHEA)
and DHEA-sulfate (DHEA-S) in Alzheimer’s disease and in cerebrovascular dementia.
Endocr J 1996;43:119–23.
Birkenhager-Gillesse EG, Derksen J, Lagaay AM. Dehydroepiandrosterone sulphate
(DHEAS) in the oldest old, aged 85 and over. Ann N Y Acad Sci
1994;719:543–52.
Schneider LS, Hinsey M, Lyness S. Plasma dehydroepiandrosterone sulfate in
Alzheimer’s disease. Biol Psychiatry 1992;31:205–8.
Gaby AR. Research review. Nutr Healing, 1996;Jan:7.
Casson PR, Buster JE. DHEA replacement after menopause: HRT 200 or nostrum of
the ‘90s? Contemporary OB/GYN 1997;Apr:119–33.
Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal
androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in
healthy young females after dexamethasone suppression. J Clin Endocrinol Metab
1998;83:1928–34.
Parasrampuria J, Schwartz K, Petesch R. Quality control of
dehydroepiandrosterone dietary supplement products. JAMA 1998;280:1565 [letter].
van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL. Treatment of
systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
J Rheumatol 1998;25:285–9.
Markowitz JS, Carson WH, Jackson CW. Possible dihydroepiandrosterone-induced
mania. Biol Psychiatry 1999;45:241–2.
Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological
dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly
women and men. J Clin Endocrinol Metab 1997;82:2263–7.
Bowers LD. Oral dehydroepiandrosterone supplementation can increase the
testosterone/epitestosterone ratio. Clin Chem 1999;45:295–6.
Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of DHEA
in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360.
Orner GA, Mathews C, Hendricks JD, et al. Dehydroepiandrosterone is a complete
hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in
rainbow trout. Carcinogenesis 1995;16:2893–8.
Metzger C, Mayer D, Hoffmann H, et al. Sequential appearance and
ultrastructure of amphophilic cell foci, adenomas, and carcinomas in the liver of male and
female rats treated with dehydroepiandrosterone. Toxicol Pathol
1995;23:591–605.
McNeil C. Potential drug DHEA hits snags on way to clinic. J Natl Cancer
Inst 1997;89:681–3.
Jones JA, Nguyen A, Strab M, et al. Use of DHEA in a patient with advanced
prostate cancer: a case report and review. Urology 1997;50:784–8.
Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma
concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with
primary operable breast cancer. Cancer Res 1981;41:3360–3.
Helzlsouer KJ, Gordon GB, Alberg AJ, et al. Relationship of prediagnostic
serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of
developing premenopausal breast cancer. Cancer Res 1992;52:1–4.
Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum
estrogen and androgen levels to breast cancer risk. Cancer Epidemiol Biomarkers Prev
1996;5:533–9.
Gordon GB, Bush TL, Helzlsouer KJ, et al. Relationship of serum levels of
dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing
postmenopausal breast cancer. Cancer Res 1990;50:3859–62.
Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause
and subsequent breast cancer. J Natl Cancer Inst 1996;88:291–6.
Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels
and risk of breast cancer in postmenopausal women. J Natl Cancer Inst
1998;90:1292–9.
Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma
concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with
primary operable breast cancer. Cancer Res 1981;41:3360–3.
Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, et al. Relation of serum levels
of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal
women. Am J Epidemiol 1997;145:1030–8.
Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and
breast cancer risk. Cancer Res 1990;50:6571–4.
Bernstein L, Ross RK, Pike MC, et al. Hormone levels in older women: a study
of post-menopausal breast cancer patients and healthy population controls. Br J
Cancer 1990;61:298–302.
Johannes CB, Stellato RK, Feldman HA, et al. Relation of
dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk
factors in women: longitudinal results from the Massachusetts Women’s Health Study.
J Clin Epidemiol 1999;52:95–103.
Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment
with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body
composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf)
1998;49:421–32.
Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid
hormones and the development of ovarian cancer. JAMA 1995;274:1926–30.
Heinonen PK, Koivula T, Pystynen P. Decreased serum level of
dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. Gynecol Obstet
Invest 1987;23:271–4.
Schwartz AG. Inhibition of spontaneous breast cancer formation in female C3H
(A vy/a) mice by long-term treatment with dehydroepiandrosterone. Cancer Res
1979;39:1129–32.
Sahelian R. New supplements and unknown, long-term consequences. Am J
Natural Med 1997;4:8 [editorial].
Schunkert H, Hense H-W, Andus T, et al. Relation between
dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. Am
J Hypertens 1999;12:1140–3.
Hautanen A, Manttari M, Manninen V, et al. Adrenal androgens and testosterone
as coronary risk factors in the Helsinki Heart Study. Atherosclerosis
1994;105:191–200.
Kiechl S, Willeit J, Bonora E, et al. No association between
dehydroepiandrosterone sulfate and development of atherosclerosis in a prospective population
study (Bruneck Study). Arterioscler Thromb Vasc Biol 2000;20:1094–100.
Suzuki M, Kanazawa A, Hasegawa M, et al. A close association between insulin
resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension.
Endocr J 1999;46:521–8.
Casson PR, Santoro N, Elkind-Hirsch K, et al. Postmenopausal
dehydroepiandrosterone administration increases free insulin-like growth factor-I and
decreases high-density lipoprotein: a six-month trial. Fertil Steril
1998;70:107–10.